Skip to content

BioRhythms: What's happening now in healthcare communications.

Caffeination for Cause




It’s caffeination for a cause.

Local companies Cambridge BioMarketing and BeanTowne Coffee House & Cafe have joined together to create a unique way to observe Rare Disease Day on February 29. With The First Annual Coffee Fix: A Benefit for Rare Disease Day, BeanTowne will donate 5% of its profits to the National Organization for Rare Disorders (NORD) on Rare Disease Day (2/29/12) to be matched by Cambridge BioMarketing. The purpose of the event is to focus attention on the needs of patients and families affected by rare diseases.

“We invite everyone from the community to come by and help us observe Rare Disease Day, have a coffee or a sandwich, and feel really good about what they’re doing,” said Maureen Franco, Chief Strategy Officer of Cambridge BioMarketing.

“So many of our local customers and companies are developing new drugs for rare disorders; we think this is a great way to celebrate their research and raise money for a great organization,” said Meg Taintor, manager of BeanTowne.

Taintor added that prices will not be higher than normal during the Coffee Fix event.

“Same prices, same great service. The more people who come and dine with us, the more support goes to rare diseases,” she said.

The First Annual Coffee Fix: February 29, 2012 7AM–5PM

BeanTowne Coffee House & Cafe

1 Kendall Square, Cambridge, Massachusetts 02139

 

About rare diseases

In the United States, any disease affecting fewer than 200,000 Americans is considered rare.  According to the National Institutes of Health (NIH), there are nearly 7000 such diseases affecting nearly 30 million Americans.

Studies have shown that it often takes 5 years or longer to get an accurate diagnosis of a rare disease.  In addition, only about 200 of the diseases classified as rare have approved treatments.

The challenges of living with a rare disease include:

  • Difficulty getting a timely, accurate diagnosis
  • Too little research
  • Too few treatments
  • Reimbursement or other issues affecting access to treatments
  • A sense of isolation
  • Difficulty finding medical experts

 

About Rare Disease Day

Rare Disease Day was launched by EURORDIS (Rare Diseases Europe) in 2008.  Last year, it was observed in more than 60 countries, with a national sponsor in each country.  NORD is the sponsor in the United States.

“This is a global observance,” said Peter L. Saltonstall, president and CEO of NORD.  “Individuals and organizations around the world will all be sharing stories of how rare diseases affect their lives.”

More than 500 patient organizations, government entities, research institutions, and companies developing treatments have signed up as Rare Disease Day partners on the national website hosted by NORD (www.rarediseaseday.us).  Cambridge BioMarketing, the world’s leading orphan and specialty drug communications company, is one of those partners.

Each year, a global planning team selects a theme for Rare Disease Day.  The theme for 2012 is, “Rare but strong together.”

Rare Disease Day activities in the United States will include a “Handprints Across America” campaign to create a gallery of photos on the Rare Disease Day website, educational materials for classroom teachers, and a nationwide blitz of patient photos, stories, and videos to increase awareness of specific rare diseases and the challenges of living with a rare disease.

Several special events are planned, including a scientific symposium at the National Institutes of Health (NIH) and a Rare Disease Patient Advocacy Day at the Food and Drug Administration (FDA).

“Since many of these diseases are genetic, more than half of the people who have rare diseases are children,” Saltonstall said. “The problems encountered by families are enormous.  It’s important for these families to know they are not alone.”

 

About NORD

NORD was established in 1983.  It provides advocacy, education, research, and patient services on behalf of rare disease patients, families, and patient organizations.

 

About Cambridge BioMarketing

Orphan products represent the best of medicine—and the best of humanity. That’s why they’re our primary focus. As the world’s leading orphan and specialty drug communications company, our services include strategic consulting, brand planning, and brand management, as well as professional marketing communications and direct-to-patient communications. Our work is award-winning, but more important, we believe it’s life-changing. For patients. Physicians. And for our clients.

 

About BeanTowne Coffee House & Café

We take your coffee, food, and happiness seriously. We know life is complicated and stressful and sometimes not very nice, so we work hard to make the food you eat, the coffee you drink, and the time you spend here at BeanTowne the very best of your day.

 

###

Tags: , , , ,

Maureen Franco Joins CB as Chief Strategy Officer

Orphan pharmaceuticals veteran Maureen FrancoCAMBRIDGE, Mass. — Cambridge BioMarketing (CB), a full-service healthcare marketing communications agency focused on orphan and specialty pharmaceuticals, names industry veteran Maureen Franco as Partner, Chief Strategy Officer.

In this new position, Ms Franco will “unify our Account Management, Clinical Sciences, and Digital Services departments into a best-in-class strategic group focused in orphan and specialty markets. And her global commercialization experience from industry adds a broader relevance and deeper resonance to the capabilities we bring to our clients,” according to CB CEO and Chief Creative Officer, Steve West.

Prior to joining CB, Ms. Franco spent 12 years at Genzyme in Cambridge where she held a number of executive leadership roles in commercial development, product marketing, global brand management, and product promotions. The last position she held was VP Global Marketing in their rare genetic disease division. Ms. Franco is a graduate of Boston College. She began her career in healthcare public relations and pharmaceutical advertising in Boston and Chicago.

“Many of our clients are developing first-ever therapies for rare or specialized conditions where the disease requires as much definition as the drug. We’re lucky to have someone of Maureen’s caliber to lead the strategic collaboration it takes to solve those unique brand challenges, “ added Mr. West.

Tags: , , ,

Holidayitis Awareness Week

Do you or a loved one suffer from Holidayitis?

At the agency, a big part of what we do is framing disease states for orphan and specialty spaces. For the 2011 holiday season, we invented our own disease and got the entire agency involved. We knew we could strategize, project manage, write, and do some pretty damn good design. But who knew we could act?

Check out Holidayitis.com—and let your friends and colleagues know about it, too. Because for every unique site visit, we’re making a donation to support orphan disease research.

Here’s wishing you a great holiday season and a happy new year!

Tags: , , , , , , , ,

The Computer Will See You Now

Diagnosis is one of the most challenging aspects of working in the rare disease space.  A recent partnership between IBM and Wellpoint, a health benefits company, might signal a dramatic shift in how patient diagnoses are made.

IBM's Watson

IBM's 'Watson' supercomputer to be used in the healthcare sector.

 

Watson, IBM’s supercomputer, has taken on chess champions and Jeopardy! contestants. It is about to get its first real-world application in the healthcare sector. WellPoint is working with IBM to develop and launch Watson-based solutions to help “improve patient care through the delivery of up-to-date, evidence-based health care for millions of Americans.”

Wellpoint’s press release states that, “Watson can sift through an equivalent of about 1 million books or roughly 200 million pages of data, and analyze this information and provide precise responses in less than three seconds. Using this extraordinary capability WellPoint is expected to enable Watson to allow physicians to easily coordinate medical data programmed into Watson with specified patient factors, to help identify the most likely diagnosis and treatment options in complex cases.”

Watson’s potential to aid in diagnosis is amazing – and indicative of the shift in how technology has become critical in healthcare. In one test case cited by WellPoint, Watson was able to diagnose a rare disease within seconds – a case that had previously left doctors baffled.

Patients are not just data sets, though.

Practicing medicine requires a human element. Someone must perform exams, take patient histories, observe symptoms, present diagnosis, and aid in care. Diagnosis is more than seeing; it’s perceiving and placing those perceptions within the context of a patient’s clinical experiences. There is collaboration between patient and doctor in determining what is wrong.

Will the human skills of medicine (listening, communication, empathy) become more critical as technology evolves? Or will accurate data collection be the focus? Will Watson ever be asked to provide differential diagnosis? Will health insurers allow for a second opinion when they have Watson?

As marketers in the rare disease state, will disease-state education for both HCPs and patients become even more valuable? As patients, will Watson be a comforting solution for diagnosis?

Tags: , ,